WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Wednesday, November 13, 2019 
Add Press Release News | News Feeds Feeds | Email This News Email


Mitochondrial Disease Therapies Market, 2019-2030
Thursday, October 24, 2019

DUBLIN, Oct. 16, 2019 /PRNewswire/ -- The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The Mitochondrial Disease Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of therapeutics designed to treat mitochondrial diseases. It features an in-depth analysis, highlighting the capabilities of stakeholder companies/organizations engaged in this domain.

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view of the state of the market for mitochondrial diseases, in the short-mid term and long term.

Chapter 3 provides a general overview of the structure and function of mitochondria and the pattern of mitochondrial inheritance. The chapter lays emphasis on genetic diseases caused due to mutations in the mitochondrial DNA and clinical conditions that are associated with mitochondrial dysfunction. It also highlights the diverse strategies that are available / being investigated for the treatment of mitochondrial diseases and key challenges/drivers associated with this segment of the pharmaceutical industry.

Chapter 4 includes information on nearly 60 molecules that are currently under development for the treatment of various mitochondrial diseases. It features a comprehensive analysis of pipeline molecules, highlighting phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), path to clinic (dedicated, repurposed and repositioned), target indication, and route of administration of the drugs / therapies that are being developed for the treatment of different mitochondrial diseases. In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength.

Chapter 5 provides detailed profiles of some of the leading stakeholders in this field (shortlisted on the basis of number/stage of the products). Each profile presents a brief overview of the company, its financial information (if available), product portfolio, recent collaborations, and an informed future outlook.

Chapter 6 provides a detailed analysis of close to 200 research articles related to therapies for mitochondrial diseases, published in the period 2014-2019 (till February). The analysis takes into consideration several aspects, namely target disease indications, mutations studies across different indications, and analysis based on various relevant parameters, such as study type (review article, research article and case reports), year of publication, and most popular journals (in terms of number of articles published in the given time period), within this domain.

Chapter 7 features a discussion on the popular secondary mitochondrial diseases, which have not been included in the scope of the report but are important to highlight. It provides information on the role of mitochondria in disease pathogenesis, laying emphasis on the various treatment strategies available / under development, to treat such clinical conditions. The chapter also presents a list of companies that have undertaken initiatives to develop drug/therapy candidate for the treatment of the aforementioned disorders.

Chapter 8 provides information on the various grants that were awarded to research institutes conducting projects related to different types of mitochondrial diseases, between 2015 and 2019 (till May). The analysis also highlights important parameters associated with grants, such as year of the award, support period, the amount awarded, funding institute, grant type, responsible study section, focus area and type of recipient organization.

Chapter 9 provides an analysis of KOLs in the field of mitochondrial diseases. It features a comprehensive list of principal investigators/study directors of different clinical trials, along with the information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists/researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The credibility and (relative) level of expertise of different KOLs defined by other analysts/industry experts were compared to the results obtained using proprietary scoring criteria, which was based on number of publications, number of citations, number of clinical trials, number of affiliations and extent of their professional network.

Chapter 10 features a detailed market forecast analysis, highlighting the likely growth of mitochondrial disease therapies till the year 2030. We have provided inputs on the likely distribution of the opportunity based on across different target indications (Leigh syndrome, LHON, MELAS, mitochondrial DNA depletion syndrome, mitochondrial myopathy, and others), type of therapy (combination and monotherapy), route of administration (oral, intravenous, and others) and key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the mitochondrial disease therapeutics industry.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 13 is an appendix, which contains a list of companies and organizations mentioned in this report.

Companies Mentioned

    --  Aadi Bioscience
    --  Adelphi University
    --  Advanced Imaging Research Center
    --  Akron Children's Hospital
    --  Al-Mumtaz Medical Complex
    --  Albert Einstein College of Medicine
    --  Alkeus Pharmaceuticals
    --  Athena Diagnostics
    --  AveXis
    --  B-MoGen Biotechnologies
    --  Bascom Palmer Eye Institute
    --  Baylor College of Medicine
    --  Beth Israel Deaconess Medical Center
    --  BioElectron Technology
    --  Biovista
    --  Brescia University
    --  BridgeBio Pharma
    --  CENTOGENE
    --  Cerecor
    --  Chiang Mai University
    --  Dana-Farber Cancer Institute
    --  Duke University
    --  ElexoPharm
    --  Eloxx Pharmaceuticals
    --  Emory School of Medicine
    --  Erasme Hospital
    --  Esousa Holdings
    --  Huazhong University of Science & Technology
    --  Illumina
    --  Innocoll
    --  Institut de la Vision
    --  Insulet
    --  IRCCS Eugenio Medea
    --  Ixchel Pharma
    --  Janssen Pharmaceuticals
    --  Joslin Diabetes Center
    --  Jupiter Orphan Therapeutics
    --  Karolinska Institutet
    --  Khondrion
    --  MD Stem Cells
    --  Medical Center of the University of Munich
    --  Medosome Biotec
    --  Wave Life Sciences
    --  Weill Cornell Medicine
    --  Wellcome Centre for Mitochondrial Research
    --  Whitehead Institute for Biomedical Research
    --  Woodinville Psychiatric Associates
    --  Yale University
    --  YUNGJIN Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/r/vvq5o9

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/mitochondrial-disease-therapies-market-2019-2030-300939647.html

SOURCE Research and Markets



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Announcing the Launch of Emblasoft, Bringing an Outstanding Portfolio of Service Enablement, Performance Management and Test and Verification Solutions to the Mobile Industry | Nov 13, 2019
Nav The global cybersecurity market was valued at USD 118.78 billion in 2018, and is expected to reach USD 267.73 billion by 2024, registering a CAGR of 14.5%, during the period of 2019 | Nov 13, 2019
Nav Sage Growth Partners Publishes New Survey Findings on Healthcare Venture Capital | Nov 13, 2019
Nav Global trail camera market is expected to grow with a CAGR of 6.2% over the forecast period from 2019-2025 | Nov 13, 2019
Nav Global sterols market is expected to grow with a CAGR of 8.2% over the forecast period from 2019-2025 | Nov 13, 2019
Nav Jivox Launches IQiD: A First-Party Deterministic Identity Graph Offering for Personalizing Dynamic Creative Without Third-Party Cookies | Nov 13, 2019
Nav Accomplished Attorney Jennifer Chung is Named AccuWeather General Counsel | Nov 13, 2019
Nav Dean Sonderegger to Lead Panel on the Future of Legal Innovation at Ark Group's Second Annual Law Firm Innovation Summit | Nov 13, 2019
Nav Global brine concentration technology market is expected to grow with a CAGR of 3.8% over the forecast period from 2019-2025 | Nov 13, 2019
Nav The enterprise asset management (EAM) market is projected to generate a revenue of $8.7 billion by 2024, advancing at a CAGR of 13.5% | Nov 13, 2019
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News